Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Renal glucose metabolism in normal physiological conditions and in diabetes.

Alsahli M, Gerich JE.

Diabetes Res Clin Pract. 2017 Nov;133:1-9. doi: 10.1016/j.diabres.2017.07.033. Epub 2017 Aug 7. Review.

PMID:
28866383
2.

Hypoglycemia in Patients with Diabetes and Renal Disease.

Alsahli M, Gerich JE.

J Clin Med. 2015 May 13;4(5):948-64. doi: 10.3390/jcm4050948. Review.

3.

Hypoglycemia, chronic kidney disease, and diabetes mellitus.

Alsahli M, Gerich JE.

Mayo Clin Proc. 2014 Nov;89(11):1564-71. doi: 10.1016/j.mayocp.2014.07.013. Epub 2014 Oct 11. Review.

PMID:
25305751
4.

SGLT2 inhibitors in the treatment of type 2 diabetes.

Hasan FM, Alsahli M, Gerich JE.

Diabetes Res Clin Pract. 2014 Jun;104(3):297-322. doi: 10.1016/j.diabres.2014.02.014. Epub 2014 Mar 11. Review.

PMID:
24735709
5.

Hypoglycemia.

Alsahli M, Gerich JE.

Endocrinol Metab Clin North Am. 2013 Dec;42(4):657-76. doi: 10.1016/j.ecl.2013.07.002. Review.

PMID:
24286945
6.

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, Gerich JE.

Diabetes Care. 2013 Oct;36(10):2945-51. doi: 10.2337/dc12-2709. Epub 2013 May 22.

7.

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).

Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 GetGoal-Mono Study Investigators.

Diabetes Care. 2012 Jun;35(6):1225-31. doi: 10.2337/dc11-1935. Epub 2012 Mar 19.

8.

Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.

Gerich JE, Bastien A.

Expert Rev Clin Pharmacol. 2011 Nov;4(6):669-83. doi: 10.1586/ecp.11.54. Review.

PMID:
22111852
9.

Effect of hyperthyroidism on clearance and secretion of glucagon in man.

Dimitriadis G, Hatziagelaki E, Mitrou P, Lambadiari V, Maratou E, Raptis AE, Gerich JE, Raptis SA.

Exp Clin Endocrinol Diabetes. 2011 Apr;119(4):214-7. doi: 10.1055/s-0030-1269880. Epub 2011 Jan 24.

PMID:
21264806
10.

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.

Gerich JE.

Diabet Med. 2010 Feb;27(2):136-42. doi: 10.1111/j.1464-5491.2009.02894.x. Review.

11.

Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.

Aryangat AV, Gerich JE.

Vasc Health Risk Manag. 2010 Mar 24;6:145-55. Review.

12.

Diabetes mellitus and gastric emptying: questions and issues in clinical practice.

Samsom M, Bharucha A, Gerich JE, Herrmann K, Limmer J, Linke R, Maggs D, Schirra J, Vella A, Wörle HJ, Göke B.

Diabetes Metab Res Rev. 2009 Sep;25(6):502-14. doi: 10.1002/dmrr.974. Review.

PMID:
19610128
13.

Is a history of gestational diabetes related to risk factors for coronary heart disease?

King KB, Gerich JE, Guzick DS, King KU, McDermott MP.

Res Nurs Health. 2009 Jun;32(3):298-306. doi: 10.1002/nur.20325.

PMID:
19274765
14.

Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide.

Woerle HJ, Albrecht M, Linke R, Zschau S, Neumann C, Nicolaus M, Gerich JE, Göke B, Schirra J.

Diabetes Care. 2008 Dec;31(12):2325-31. doi: 10.2337/dc07-2446.

15.

Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors.

Gerich JE.

Clin Cornerstone. 2007;8(3):53-68. Review.

PMID:
18452842
16.

Glycemic control in the metabolic syndrome and implications in preventing cardiovascular disease.

Gerich JE.

Metab Syndr Relat Disord. 2006 Winter;4(4):315-27. doi: 10.1089/met.2006.4.315.

PMID:
18370749
17.

Effect of aging on glucose homeostasis: accelerated deterioration of beta-cell function in individuals with impaired glucose tolerance.

Szoke E, Shrayyef MZ, Messing S, Woerle HJ, van Haeften TW, Meyer C, Mitrakou A, Pimenta W, Gerich JE.

Diabetes Care. 2008 Mar;31(3):539-43. Epub 2007 Dec 14.

PMID:
18083793
18.

Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.

Schwarz SL, Gerich JE, Marcellari A, Jean-Louis L, Purkayastha D, Baron MA.

Diabetes Obes Metab. 2008 Aug;10(8):652-60. Epub 2007 Oct 15.

PMID:
17941876
19.
20.

Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease.

Mieszczanska H, Kaba NK, Francis CW, Gerich JE, Dodis R, Schwarz KQ, Phipps RP, Smith BH, Lee M, Messing S, Taubman MB.

J Thromb Haemost. 2007 May;5(5):942-9.

21.

The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.

Dunning BE, Gerich JE.

Endocr Rev. 2007 May;28(3):253-83. Epub 2007 Apr 4. Review.

PMID:
17409288
22.

Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels.

Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, Gerich JE, Göke B.

Diabetes Res Clin Pract. 2007 Aug;77(2):280-5. Epub 2007 Jan 22.

PMID:
17240473
23.
24.

Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus.

Israelian Z, Szoke E, Woerle J, Bokhari S, Schorr M, Schwenke DC, Cryer PE, Gerich JE, Meyer C.

Metabolism. 2006 May;55(5):593-8.

PMID:
16631434
25.

Postprandial hyperglycemia and cardiovascular disease.

Gerich JE.

Endocr Pract. 2006 Jan-Feb;12 Suppl 1:47-51. Review.

PMID:
16627380
26.

Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia.

Szoke E, Gosmanov NR, Sinkin JC, Nihalani A, Fender AB, Cryer PE, Meyer C, Gerich JE.

Metabolism. 2006 Jan;55(1):78-83.

PMID:
16324923
27.

Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes.

Israelian Z, Gosmanov NR, Szoke E, Schorr M, Bokhari S, Cryer PE, Gerich JE, Meyer C.

Diabetes Care. 2005 Nov;28(11):2691-6.

PMID:
16249541
28.

The importance of tight glycemic control.

Gerich JE.

Am J Med. 2005 Sep;118(Suppl 9A):7S-11S. Review.

PMID:
16224937
29.

Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes.

Woerle HJ, Szoke E, Meyer C, Dostou JM, Wittlin SD, Gosmanov NR, Welle SL, Gerich JE.

Am J Physiol Endocrinol Metab. 2006 Jan;290(1):E67-E77. Epub 2005 Aug 16.

30.

Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial.

Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC; Inhaled Insulin Phase III Type 1 Diabetes Study Group.

Diabetes Care. 2005 Jul;28(7):1630-5.

PMID:
15983312
31.
32.

Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans.

Gosmanov NR, Szoke E, Israelian Z, Smith T, Cryer PE, Gerich JE, Meyer C.

Diabetes Care. 2005 May;28(5):1124-31.

PMID:
15855577
33.

Advances in diabetes for the millennium: understanding insulin resistance.

Gerich JE, Dailey G.

MedGenMed. 2004 Aug 26;6(3 Suppl):11. Review.

34.

Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.

Fonseca VA, Kelley DE, Cefalu W, Baron MA, Purkayastha D, Nestler JE, Hsia S, Gerich JE.

Metabolism. 2004 Oct;53(10):1331-5. Erratum in: Metabolism. 2005 May;54(5):698.

PMID:
15375790
35.

Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes.

Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE.

Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1049-56. Epub 2004 Aug 10.

36.

Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values.

Woerle HJ, Pimenta WP, Meyer C, Gosmanov NR, Szoke E, Szombathy T, Mitrakou A, Gerich JE.

Arch Intern Med. 2004 Aug 9-23;164(15):1627-32.

PMID:
15302632
37.

Insulin glargine: long-acting basal insulin analog for improved metabolic control.

Gerich JE.

Curr Med Res Opin. 2004 Jan;20(1):31-7. Review.

PMID:
14741069
38.

Clinical significance, pathogenesis, and management of postprandial hyperglycemia.

Gerich JE.

Arch Intern Med. 2003 Jun 9;163(11):1306-16. Review.

PMID:
12796066
39.
40.
41.

Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens.

Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL, Gerich JE.

Diabetes. 2003 Apr;52(4):918-25.

42.

Role of the kidney in hyperglycemia in type 2 diabetes.

Meyer C, Gerich JE.

Curr Diab Rep. 2002 Jun;2(3):237-41. Review.

PMID:
12643179
43.

Insulin secretion, insulin sensitivity, and hepatic insulin extraction in first-degree relatives of type 2 diabetic patients.

Pimenta WP, Santos ML, Cruz NS, Aragon FF, Padovani CR, Gerich JE.

Braz J Med Biol Res. 2003 Mar;36(3):301-8. Epub 2003 Mar 7.

44.

Hepatorenal glucose reciprocity in physiologic and pathologic conditions.

Gerich JE.

Diabetes Nutr Metab. 2002 Oct;15(5):298-302; discussion 302-3. Review. No abstract available.

PMID:
12625473
45.

Brazilian individuals with impaired glucose tolerance are characterized by impaired insulin secretion.

Pimenta WP, Santos ML, Cruz NS, Aragon FF, Padovani CR, Gerich JE.

Diabetes Metab. 2002 Dec;28(6 Pt 1):468-76.

PMID:
12522327
46.

Pathways for glucose disposal after meal ingestion in humans.

Woerle HJ, Meyer C, Dostou JM, Gosmanov NR, Islam N, Popa E, Wittlin SD, Welle SL, Gerich JE.

Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E716-25. Epub 2002 Dec 10.

47.

Novel insulins: expanding options in diabetes management.

Gerich JE.

Am J Med. 2002 Sep;113(4):308-16. Review.

PMID:
12361817
48.

Autoregulation of endogenous glucose production during hyperglucagonemia.

Toft I, Gerich JE, Jenssen T.

Metabolism. 2002 Sep;51(9):1128-34.

PMID:
12200756
49.

Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology.

Gerich JE.

Eur J Clin Invest. 2002 Jun;32 Suppl 3:46-53. Review.

PMID:
12028374
50.

Disturbances in beta-cell function in impaired fasting glycemia.

van Haeften TW, Pimenta W, Mitrakou A, Korytkowski M, Jenssen T, Yki-Jarvinen H, Gerich JE.

Diabetes. 2002 Feb;51 Suppl 1:S265-70.

Supplemental Content

Loading ...
Support Center